A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg alone

Trial Profile

A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg alone

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Amlodipine/valsartan (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Feb 2009 Results have been published in the International Journal of Clinical Practice.
    • 24 Jul 2008 Status change
    • 19 Jun 2008 Status change from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top